Bone Substitute Articles & Analysis
18 news found
Milan, Italy (June 1st, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2022 IFSSH, IFSHT & FESSH Combined Congress organized by the International Federation of Societies for Surgery of the Hand and International Federation of Societies for Hand ...
ByKLISBio
Milan, Italy (May 11, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2022 Bio€quity Europe. 2022 Bio€quity Europe will be held May 16 -18, 2022 in Milan – Italy. Antonio Alessandrino, CTO and Founder of KLISBio, will be presenting on ...
ByKLISBio
Milan, Italy (March 23, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance 2022 American Academy of Orthopaedic Surgeons Annual Meeting. The event will be held March 22-26 in Chicago -IL. KLISBio’s designated attendee to 2022 AAOS Congress is Jason ...
ByKLISBio
Milan, Italy (March 22, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2022 CG Musculoskeletal Conference. Ahead of the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting March 22-26, 2022 in Chicago, Canaccord Genuity will host its CG ...
ByKLISBio
Milan, Italy (March 21, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance 2022 Digital RESI. The conference will be held March 22-24, 2022 through a virtual platform. KLISBio’s designated attendee to Digital RESI Conference is Gabriele Grecchi, CEO ...
ByKLISBio
Milan, Italy (March 14, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to LSI 2022 Emerging MedTech Summit. LSI Annual Meeting will be held March 15 -18, 2022 in Dana Point – CA. KLISBio’s designated attendee to LSI Emerging MedTech Summit ...
ByKLISBio
Hyalex Orthopaedics, a privately-held medical device company developing transformational cartilage biomimetic products, today announced the appointment of Carl Vause as its new chief executive officer and president. Mr. Vause, who succeeds Hyalex’s interim president, Michael Hawkins, Ph.D., has also been appointed to the company’s board of directors. Additionally, Dr. Hawkins has ...
Among the best of new innovations in life sciences and biomedicine being unveiled to investors and healthcare leaders at JP Morgan’s BIO Partnering conference this month is KLISBio’s silk-based biomedical technology. Among the company’s developing portfolio of products is SILKBridge®, a first-to-market, silk-based graft for peripheral nerve repair, which is anticipated ...
ByKLISBio
With the profound impact on patients’ quality of life, peripheral nerve injuries remain at the forefront of treatment challenges for orthopedic surgeons. That’s a driving force behind KLISBio’s SILKBridge®, a first-to-market solution for peripheral nerve repair. KLISBio will introduce SILKBridge® to attendees at the American Association for Hand Surgeons Annual Meeting ...
ByKLISBio
Investors keen to get involved with a company on the forefront of human tissue regeneration will be interested to visit with KLISBio, an international medtech company bringing its silk-based biomedical technology and the first of their products, SILKBridge®, to the Biotech Showcase Jan. 10-19. KLISBio is leading a revolution in restorative surgical procedures using engineered silk ...
ByKLISBio
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has submitted a supplementary De Novo application to the US Food and Drug Administration (FDA) to obtain a market approval for the company’s antibiotic-releasing product CERAMENT® G. The application is specified for the indication osteomyelitis (bone infection) ...
CARLSBAD, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it received simultaneous CE Mark certification for its Cranial Module and Percutaneous Spine Module for the 7D FLASH™ Navigation System. This achievement expands the ...
CARLSBAD, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the FDA 510(k) clearance of its 7D Percutaneous Spine Module for minimally invasive surgery. This represents a new application and increased functionality for its 7D Flash™ ...
CARLSBAD, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of the previously announced acquisition of 7D Surgical. 7D Surgical is a Toronto-based company that develops advanced optical technologies and machine vision-based ...
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, has been awarded a group purchasing agreement for Synthetic Implantable Products with Premier. Effective July 1st, the new agreement allows Premier members, at their discretion, to take advantage of pricing and terms pre-negotiated by Premier for CERAMENT® BONE VOID FILLER. “The awarded ...
FDA’s Breakthrough Device Program helps accelerate patient access to more effective treatments Locate Bio, an orthobiologics focused regenerative medicine company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to CognitOss, currently in develoment for the treatment of chronic osteomyelitis. The FDA Breakthrough Device ...
GRAFTYS SA (“Graftys”), a global leader in resorbable bone cements, is proud to announce that as a fruitful result of 10 years’ partnership with its distributor - LAS Brasil, the milestone of 10,000 units of GRAFTYS® HBS sold in Brazil has been crossed during the third quarter of 2020. GRAFTYS® HBS is a calcium phosphate bone graft substitute, which offers very low ...
ByGraftys
On August 7, 2019, Molecular Matrix, Inc. (MMI) announced the signing of a Memorandum of Understanding (MOU) with Philosys Healthcare Co., Ltd., a biomedical distribution and manufacturing company based in Seongnam, South Korea. MMI is a biotechnology company that began as a startup at UC Davis, and after more than 10 years of research and development has created a scaffold for bone tissue ...